| pubmed-article:8495711 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8495711 | lifeskim:mentions | umls-concept:C0684336 | lld:lifeskim |
| pubmed-article:8495711 | lifeskim:mentions | umls-concept:C0011065 | lld:lifeskim |
| pubmed-article:8495711 | lifeskim:mentions | umls-concept:C0010097 | lld:lifeskim |
| pubmed-article:8495711 | lifeskim:mentions | umls-concept:C0162512 | lld:lifeskim |
| pubmed-article:8495711 | lifeskim:mentions | umls-concept:C0521390 | lld:lifeskim |
| pubmed-article:8495711 | lifeskim:mentions | umls-concept:C0521451 | lld:lifeskim |
| pubmed-article:8495711 | lifeskim:mentions | umls-concept:C0449864 | lld:lifeskim |
| pubmed-article:8495711 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:8495711 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:8495711 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8495711 | pubmed:dateCreated | 1993-6-24 | lld:pubmed |
| pubmed-article:8495711 | pubmed:abstractText | There may be important relationships between glutamate receptor activation and neurotoxicity in neurodegenerative diseases. Previous experiments using cultured neurons have demonstrated a correlation between the metabolic status of neurons and their sensitivity to glutamate receptor-mediated cytotoxicity (Novelli et al. Brain Res. 451, 205, 1988). To examine such a relationship in vivo, we first established a dose-response curve for N-methyl-D-aspartate (NMDA)-induced neuronal death in the rat striatum. We then examined the interaction between metabolic impairment and infusion of NMDA at a dose below the threshold for neurotoxicity. Metabolic impairment was induced by intraperitoneal delivery of 3-nitropropionic acid (3-NP), an inhibitor of mitochondrial complex II (succinic dehydrogenase). Twelve hours after 3-NP delivery we performed stereotactic infusion of NMDA or vehicle into the striatum. During mitochondrial impairment, a relatively nonneurotoxic dose of NMDA (15 nmol) produced a lesion that was significantly larger than that caused by this dose under normal metabolic conditions. At a dose normally below the threshold for neurotoxicity, metabolic impairment significantly increased the likelihood of neuronal death in the striatum by a factor of 5. Lesions were characterized by neuronal loss with gliosis and sparing of traversing fiber bundles. These results demonstrate that metabolic impairment reduces the threshold for glutamate receptor-mediated neurotoxicity in vivo. This potentiation may have implications for understanding the role of "neuronal stress" produced by glutamate receptor activation in neurodegenerative diseases and normal aging. | lld:pubmed |
| pubmed-article:8495711 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8495711 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8495711 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8495711 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8495711 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8495711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8495711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8495711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8495711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8495711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8495711 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8495711 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8495711 | pubmed:month | May | lld:pubmed |
| pubmed-article:8495711 | pubmed:issn | 0014-4886 | lld:pubmed |
| pubmed-article:8495711 | pubmed:author | pubmed-author:SimpsonJ RJR | lld:pubmed |
| pubmed-article:8495711 | pubmed:author | pubmed-author:IsacsonOO | lld:pubmed |
| pubmed-article:8495711 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8495711 | pubmed:volume | 121 | lld:pubmed |
| pubmed-article:8495711 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8495711 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8495711 | pubmed:pagination | 57-64 | lld:pubmed |
| pubmed-article:8495711 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:meshHeading | pubmed-meshheading:8495711-... | lld:pubmed |
| pubmed-article:8495711 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8495711 | pubmed:articleTitle | Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. | lld:pubmed |
| pubmed-article:8495711 | pubmed:affiliation | Neuroregeneration Laboratory, McLean Hospital, Belmont, Massachusetts 02178. | lld:pubmed |
| pubmed-article:8495711 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8495711 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8495711 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8495711 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8495711 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8495711 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8495711 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8495711 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8495711 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8495711 | lld:pubmed |
